Delving into the Latest Updates on Antengene (Hangzhou) Biologics Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Other Diseases

Antibody

Bispecific antibody

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	9
Hemic and Lymphatic Diseases	8
Immune System Diseases	6
Nervous System Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Antibody	5
Bispecific antibody	3
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

4-1BB x PDL1	1
LILRB2(Leukocyte immunoglobulin-like receptor subfamily B member 2)	1
CD24(CD24 molecule)	1
B7 family	1
CD3(T cell surface glycoprotein CD3)	1

这是一项 ATG-022 在晚期实体瘤患者中的 I 期、多中心、开放性、剂量探索研究。研究设计包括剂量递增阶段（该阶段将入组晚期/转移性实体瘤受试者）和剂量扩展阶段（该阶段将入组具有 Claudin 18.2 阳性表达的选定晚期/转移性实体瘤受试者，以定义的最大耐受剂量[MTD]和/或 II 期推荐剂量[RP2D]给药）以进一步评价 ATG-022 的安全性、耐受性和疗效。

[Translation]

This is a Phase I, multicenter, open-label, dose-finding study of ATG-022 in patients with advanced solid tumors. The study design includes a dose escalation phase (which will enroll subjects with advanced/metastatic solid tumors) and a dose expansion phase (which will enroll selected subjects with advanced/metastatic solid tumors with positive Claudin 18.2 expression, dosed at a defined maximum tolerated dose [MTD] and/or recommended Phase II dose [RP2D]) to further evaluate the safety, tolerability and efficacy of ATG-022.

Start Date10 May 2023

Sponsor / Collaborator

Antengene (Hangzhou) Biologics Co., Ltd.

CTR20220652 / RecruitingPhase 1

一项ATG-101在中国晚期/转移性实体瘤和成熟B细胞非霍奇金淋巴瘤患者中的I期临床试验

[Translation] A Phase I Clinical Trial of ATG-101 in Chinese Patients with Advanced/Metastatic Solid Tumors and Mature B-Cell Non-Hodgkin Lymphoma

评价ATG-101的安全性和耐受性，确定ATG-101 的最大耐受剂量和II期推荐剂量，评价ATG-101的初步抗肿瘤活性。

[Translation]

Evaluate the safety and tolerability of ATG-101, determine the maximum tolerated dose and Phase II recommended dose of ATG-101, and evaluate the preliminary anti-tumor activity of ATG-101.

Start Date08 Jul 2022

Sponsor / Collaborator

Antengene (Hangzhou) Biologics Co., Ltd.

100 Clinical Results associated with Antengene (Hangzhou) Biologics Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Antengene (Hangzhou) Biologics Co., Ltd.

Login to view more data

100 Deals associated with Antengene (Hangzhou) Biologics Co., Ltd.

Login to view more data

100 Translational Medicine associated with Antengene (Hangzhou) Biologics Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

7

2

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ATG-022 ( CLDN18.2 )	Solid tumor More	Phase 1
Xirestomig ( 4-1BB x PDL1 )	Solid tumor More	Phase 1
WO2023236891 ( LILRB4 )Patent Mining	Nervous System Diseases More	Discovery
WO2024041315 ( LILRB2 )Patent Mining	Rare Diseases More	Discovery
WO2024099295 ( B7 family )Patent Mining	Rare Diseases More	Discovery